Prozac patent strategy
Executive Summary
Lilly does not believe aaiPharma's fluoxetine purification patent "meets FDA's standards for listing in the 'Orange Book'" and therefore decided not to "further pursue" obtaining rights to the technology, the company says. While Lilly will continue to enforce its own Prozac patents it will not engage in "last-minute legal maneuvers" to extend Prozac's exclusivity (1see related story, p. 19). Lilly indicated that public relations tactics played a role in its decision. aaiPharma's patent (6,258,853) on a pure crystalline form of fluoxetine Form A was issued by the Patent & Trademark Office July 10
You may also be interested in...
AstraZeneca Mulls AaiPharma Omeprazole Patent; Will Not List Two Others
AstraZeneca is expected to make a decision on whether to list an aaiPharma patent covering omeprazole in the "Orange Book" by the end of the month.
AstraZeneca Mulls AaiPharma Omeprazole Patent; Will Not List Two Others
AstraZeneca is expected to make a decision on whether to list an aaiPharma patent covering omeprazole in the "Orange Book" by the end of the month.
AaiPharma Fast-Acting Diclofenac NDA Filing Planned For 2002
AaiPharma plans to submit an NDA by the end of 2002 for its rapidly absorbed diclofenac, claiming a shorter time-to-peak benefit in acute pain.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: